Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of gentiopicroside in treatment of non-alcoholic fatty liver diseases
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for fatty liver disease and gentiopicroside, applied in the field of application of gentiopicroside in the treatment of non-alcoholic fatty liver disease, can solve the controversial and uncertain effects of NAFLD treatment
Inactive Publication Date: 2018-04-20
NORTHWEST UNIV
View PDF4 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, the therapeutic effect of some of the above-mentioned drugs on NAFLD is controversial or uncertain. Seeking safe and effective therapeutic drugs and methods must be a hot issue that the medical circles in various countries continue to pay attention to.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0075] Medicinal gentiopicroside is prepared into tablets. Taking the production of 1000 tablet products as an example, the raw materials and auxiliary materials used and their weight ratios are as follows:
[0078] Its preparation process is carried out according to the conventional process of pharmacy tablets, each tablet weighs 0.3 g, and each tablet contains gentiopicroside 200 mg.
[0079] Usage and Dosage: Take orally, 1 tablet each time, once a day, reduce as appropriate for children, a course of treatment is 15 days.
Embodiment 2
[0081] Medicinal gentiopicroside is prepared into capsules, taking the production of 1000 capsule products as an example, the raw materials and auxiliary materials used and their weight ratios are as follows:
[0084] Its preparation process is carried out according to the conventional process of pharmaceutical capsules, each capsule weighs 0.3 g, and each capsule contains 200 mg of gentiopicroside.
[0085] Usage and dosage: Oral, 1 capsule each time, once a day, reduce it for children, a course of treatment is 15 days.
Embodiment 3
[0087] Medicinal gentiopicroside is prepared into granules. Taking the production of 1000 granule products as an example, the raw materials and auxiliary materials used and their weight ratios are as follows:
[0091] Its preparation process is carried out according to the conventional process of pharmaceutical granules, each bag weighs 1 g, and 1 g contains gentiopicroside 200 mg.
[0092] Usage and dosage: Oral, 1 bag each time, once a day, reduce it for children, a course of treatment is 15 days.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention relates to application of gentiopicroside in preparation of medicines for treating non-alcoholic fatty liver diseases. Experiments prove that the gentiopicroside can achieve the following effects in non-alcoholic fatty liver diseases caused by fructose: obviously limiting increase of mouse weight and decrease of food ration, lowering triglycerides (TG), uric acid (UA) and glucose (GLU) as well as levels of serum glutamic oxalacetic transaminase (AST) and glutamic-pyruvic transaminase (ALT), obviously alleviating vacuolar degeneration of hepatic cells and deposition of fatty acidscaused by fructose, lowering levels of tumor necrosis factors (TNF-alpha) and interleukin 6 (IL-6) in hepatic tissues, raising levels of superoxidedismutase (SOD) and glutathioneperoxidase (GSH-Px)in the hepatic tissues and lowering levels of malondialdehyde (MDA) and superoxide anions (O2<->). Results show that the gentiopicroside can achieve the effects of obviously promoting metabolism of the liver on fat, obviously improving and increasing the antioxidantstress level of the liver and alleviating hepatocellular injury, so that the aim of treating the fatty liver diseases is achieved.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
